They have also examined the coexpression of surface vimentin with the CD44 and CD133 stem- or progenitor cell marker proteins and demonstrated that Cowpea mosaic virus (CPMV) nanoparticles can bind to the surface domains of vimentin thereby facilitating drug targeting in prostate cancer. This evidence concerns the gene CD44 and prostate carcinoma.